WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics
WuXi Biologics (WXXWY) has achieved the highest negligible-risk ESG rating from Morningstar Sustainalytics, placing the company in the top 1% globally among over 15,000 companies evaluated. The leading global Contract Research, Development, and Manufacturing Organization (CRDMO) has maintained its position as an Industry and Regional ESG Top-Rated Company for five consecutive years.
The company received the lowest risk exposure level and strongest risk management score under Sustainalytics' two-dimensional assessment framework. WuXi Biologics has also garnered multiple prestigious ESG recognitions, including an MSCI AAA rating, EcoVadis Platinum Medal, and inclusion in the Dow Jones Sustainability Indices.
WuXi Biologics (WXXWY) ha ottenuto il più alto rating ESG a rischio trascurabile da Morningstar Sustainalytics, collocando l'azienda nel top 1% a livello globale tra oltre 15.000 società valutate. L'organizzazione leader mondiale nel Contract Research, Development e Manufacturing (CRDMO) ha mantenuto la sua posizione come azienda top-rated per ESG nel settore e nella regione per cinque anni consecutivi.
L'azienda ha ricevuto il livello di esposizione al rischio più basso e il punteggio più alto nella gestione del rischio secondo il quadro di valutazione bidimensionale di Sustainalytics. WuXi Biologics ha inoltre ottenuto numerosi riconoscimenti ESG prestigiosi, tra cui un rating MSCI AAA, la Medaglia di Platino EcoVadis e l'inclusione negli Indici di Sostenibilità Dow Jones.
WuXi Biologics (WXXWY) ha alcanzado la calificación ESG de riesgo insignificante más alta de Morningstar Sustainalytics, ubicando a la empresa en el top 1% mundial entre más de 15,000 compañías evaluadas. La principal organización global de Contract Research, Development y Manufacturing (CRDMO) ha mantenido su posición como empresa mejor valorada en ESG a nivel sectorial y regional durante cinco años consecutivos.
La compañía recibió el nivel más bajo de exposición al riesgo y la puntuación más alta en gestión de riesgos según el marco de evaluación bidimensional de Sustainalytics. WuXi Biologics también ha obtenido múltiples reconocimientos ESG prestigiosos, incluyendo una calificación MSCI AAA, la Mención Platino de EcoVadis y la inclusión en los Índices de Sostenibilidad Dow Jones.
WuXi Biologics (WXXWY)는 Morningstar Sustainalytics로부터 가장 낮은 위험 수준의 ESG 등급을 획득하여, 평가된 15,000개 이상의 기업 중 전 세계 상위 1%에 위치했습니다. 세계 선도적인 계약 연구, 개발 및 제조 조직(CRDMO)으로서 5년 연속 업계 및 지역 ESG 최고 등급 기업으로 자리매김했습니다.
회사 는 Sustainalytics의 2차원 평가 체계에서 가장 낮은 위험 노출 수준과 가장 강력한 위험 관리 점수를 받았습니다. WuXi Biologics는 또한 MSCI AAA 등급, EcoVadis 플래티넘 메달, 그리고 다우존스 지속 가능성 지수 포함 등 다수의 권위 있는 ESG 인정을 받았습니다.
WuXi Biologics (WXXWY) a obtenu la note ESG à risque négligeable la plus élevée de Morningstar Sustainalytics, plaçant l'entreprise dans le top 1 % mondial parmi plus de 15 000 sociétés évaluées. Le leader mondial du Contract Research, Development, and Manufacturing Organization (CRDMO) a conservé sa position en tant que entreprise la mieux notée ESG dans son secteur et sa région pendant cinq années consécutives.
L'entreprise a reçu le niveau d'exposition au risque le plus faible ainsi que le meilleur score en gestion des risques selon le cadre d'évaluation bidimensionnel de Sustainalytics. WuXi Biologics a également reçu de nombreuses distinctions ESG prestigieuses, incluant une note MSCI AAA, une Médaille Platine EcoVadis et une inclusion dans les Indices de durabilité Dow Jones.
WuXi Biologics (WXXWY) hat die höchste ESG-Bewertung mit vernachlässigbarem Risiko von Morningstar Sustainalytics erhalten und gehört damit weltweit zu den Top 1% unter mehr als 15.000 bewerteten Unternehmen. Das weltweit führende Contract Research, Development und Manufacturing Organization (CRDMO) hat seine Position als Branchen- und regional führendes ESG-Unternehmen fünf Jahre in Folge gehalten.
Das Unternehmen erhielt das niedrigste Risikoniveau und die beste Risikomanagementbewertung im zweidimensionalen Bewertungsrahmen von Sustainalytics. WuXi Biologics hat zudem mehrere renommierte ESG-Auszeichnungen erhalten, darunter die MSCI AAA-Bewertung, die EcoVadis Platin-Medaille und die Aufnahme in die Dow Jones Nachhaltigkeitsindizes.
- Achieved highest negligible-risk ESG rating from Sustainalytics, ranking in top 1% globally
- Maintained Industry and Regional ESG Top-Rated Company status for 5 consecutive years
- Received multiple prestigious ESG recognitions including MSCI AAA rating and EcoVadis Platinum Medal
- Strong participation in global sustainability initiatives through UNGC and PSCI membership
- None.
- Best ESG rating tier of negligible-risk with a top
1% global ranking score - Industry and Regional ESG Top-Rated Company for five consecutive years
- Leader in Green CRDMO to drive innovation for a healthier future
Sustainalytics is a leading ESG data, research, and ratings firm that supports global investors with their development and implementation of responsible investment strategies. Its 2025 ESG Risk Ratings—covering more than 15,000 companies across different industries worldwide—evaluates over 20 material ESG issues through over 200 indicators and categorizes rating results across five risk levels, from the best negligible to the worst severe.
Under the two-dimensional assessment framework, WuXi Biologics achieved the lowest level of risk exposure and was given the strongest risk management score, placing it in the negligible-risk tier with a top
Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "We are very pleased to have achieved the negligible-risk rating from Morningstar Sustainalytics. It is a reflection of and recognition for WuXi Biologics' continuous commitment to enhancing sustainability capabilities. As a global leader in Green CRDMO, we are focused not only on delivering our own ESG excellence but also on enabling partners worldwide to fulfill their ESG commitments, collaborating with all stakeholders to promote responsible practices throughout the entire value chain."
As a participant of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), the company proactively contributes to advocating sustainability and has earned widespread recognitions for its efforts. It has been granted a MSCI AAA rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP Water Security "A list" and given an A- CDP Climate Change leadership-level score since 2023; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.
About Morningstar Sustainalytics
Morningstar Sustainalytics is a leading ESG data, research, and ratings firm that supports investors around the world with the development and implementation of responsible investment strategies. For more than 30 years, the firm has been at the forefront of developing high-quality, innovative solutions to meet the evolving needs of global investors. Today, Morningstar Sustainalytics works with hundreds of the world's leading asset managers and pension funds who incorporate ESG information and assessments into their investment processes. The firm also works with hundreds of companies and their financial intermediaries to help them consider material sustainability factors in policies, practices, and capital projects. Morningstar Sustainalytics has analysts around the world with varied multidisciplinary expertise across more than 40 industry groups. For more information, visit www.sustainalytics.com.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
Contacts
ESG
Media
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-granted-highest-negligible-risk-esg-rating-from-morningstar-sustainalytics-302506622.html
SOURCE WuXi Biologics
FAQ
What ESG rating did WuXi Biologics (WXXWY) receive from Morningstar Sustainalytics in 2025?
How many consecutive years has WuXi Biologics been recognized as an Industry and Regional ESG Top-Rated Company?
What other ESG recognitions has WuXi Biologics received?
What global sustainability initiatives is WuXi Biologics part of?
